An approach paper on healthcare biotechnologies in India
2018 | Sama | Heinrich Böll Foundation
The approach paper draws attention to the newer biotechnologies in healthcare, such as regenerative medicine and genomics, that have begun to make inroads into the Indian market. As legal and regulatory frameworks struggle to grapple with the ethical conundrums posed by them, these newer biotechnologies thrive in a climate of uncertainty, banking on the notion of a promissory future free of illness. Although these technologies raise newer ethical dilemmas related to questions of data privacy, ownership of biological information and patenting or what it means to be “genetically ill”, the ethical concerns related to healthcare technologies are equally relevant for the newer biotechnologies. The paper further maps the ways in which gendered imprints are writ large on emerging biotechnologies in India.
Developed by Sarojini Nadimpally, Aswathy Raveendran and Pratibha Sivasubramanian, Sama Resource Group for Women and Health